Markers such as PD-L1 and tumor mutation burden (TMB) have been proposed in the context of cellular therapy, as these may indicate a more inflammatory phenotype in the tumor, though even in the context of immune checkpoint blockade therapy, their use can be controversial [135,136]. This evidence concerns the gene CD274 and neoplasm.